Loading...
Market
What will be the total milestone payments received by Prime Medicine from Bristol Myers Squibb by September 30, 2025?
3
Resolution / Starting Odds
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Official press releases from Prime Medicine or Bristol Myers Squibb, financial reports
Story
Prime Medicine and Bristol Myers Squibb Enter $3.5 Billion T-Cell Therapy Collaboration with $110M Upfront
Sep 30, 2024, 12:38 PM
Prime Medicine has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb to develop and commercialize multiple Prime Edited Ex Vivo T-Cell Therapies. Prime Medicine will receive $110 million upfront, consisting of $55 million in cash and $55 million in equity, with the potential for more than $3.5 billion in milestone payments. The milestone payments include $1.4 billion in development milestones and $2.1 billion in commercialization milestones. The equity investment involves approximately 11 million shares at $4.99 per share. This collaboration aims to leverage Prime Medicine's gene editing expertise and Bristol Myers Squibb's cell therapy capabilities.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increases by more than 50% • 25%
Increases by 25% to 50% • 25%
Changes by less than 25% • 25%
Decreases • 25%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Yes • 50%
No • 50%
Increases by more than 20% • 25%
Increases by 10% to 20% • 25%
Changes by less than 10% • 25%
Decreases • 25%
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
None • 25%
Up to $100M • 25%
$100M to $200M • 25%
Over $200M • 25%